Combined Dosage Form Research Articles

Assessment of Aliskiren Hemifumarate and Amlodipine Besylate in combined Tablet Dosage form by Three Simple UV Spectrophotometric Methods

Background: For a cardiovascular patient's blood pressure to be effectively controlled, more than one drug is required. When coupled with amlodipine besylate (AMLO), a calcium channel blocker, Aliskiren hemifumarate (ALI) is the 1st nonpeptide, low molecular mass, orally active transition state rennin inhibitor to efficaciously normalize blood pressure and cardiac ailments.
 Objective: Three innovative, easy, sensitive, exact, and accurate UV spectrophotometric approaches, including simultaneous equation method (SEM), absorbance ratio method (ARM) and 1st derivative (zero-crossing) spectroscopic approach (FDR), were created and authenticated by validation for synchronized estimation of ALI and AMLO in tablet formulation.
 Materials and Methods: The SEM was used to measure the absorbance of both medicines at 237 and 280 nm. ALI and AMLO were calculated using 237 and 271 nm, respectively, in the ARM. ALI and AMLO, on the other hand, used the FDR technique to transform UV spectra to first derivative spectra, with the first derivative signal captured at 237 and 254 nm, respectively. The wavelength interval (Δλ) was kept at 2 and the scaling factor was kept at 1 when transforming zero-order spectra using the first derivative approach. Validation of the proposed processes was done in compliance with the “International Conference on Harmonization” (ICH) recommendations. Results: SEM and ARM both showed a linear outcome in the range of 1-50 µg/ml for ALI and AMLO. FDR, on the other hand, was shown to be more sensitive and linear between 0.5 and 50 µg/ml for both medications. The results of the method validation parameters were within the allowed ranges of the ICH guidelines.
 Conclusion: The proposed procedures were shown to be relatively quick, sensitive, simple, and cost-effective, and can thus be used for scheduled quality control analysis of ALI and AMLO in the mixed tablet.

Aspirin and omega-3 polyunsaturated fatty acid use and their interaction in cardiovascular diseases and colorectal adenomas.

Aspirin (acetylsalicylic acid, ASA) is inexpensive and is established in preventing cardiovascular disease (CVD) and colorectal adenomas. Omega-3 (n3) polyunsaturated fatty acids (PUFA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have also shown benefit in preventing CVD. The combination could be an effective preventative measure in patients with such diseases. ASA and n3 PUFA reduced the risk of CVD in ASA-resistant or diabetic patients. EPA- and DHA-deficient patients also benefited the most from n3 PUFA supplementation. Synergistic effects between ASA and EPA and DHA are 'V-shaped' such that optimal ASA efficacy is dependent on EPA and DHA concentrations in blood. In colorectal adenomas, ASA (300 mg/d) and EPA reduced adenoma burden in a location- and subtype-specific manner. Low doses of ASA (75-100 mg/d) were used in CVD prevention; however, ultra-low doses (30 mg/d) can also reduce thrombosis. EPA-to-DHA ratio is also important with regard to efficacy. DHA is more effective in reducing blood pressure and modulating systemic inflammation; however, high-dose EPA can lower CVD events in high-risk individuals. Although current literature has yet to examine ASA and DHA in preventing CVD, such combination warrants further investigation. To increase adherence to ASA and n3 PUFA supplementation, combination dosage form may be required to improve outcomes.

Simultaneous Determination and Validation of Flupirtine Maleate and Paracetamol in Combined Dosage Form by Chromatographic Technique

Objective: The focus of this research was to establish a validated high-performance thin layer chromatographic (HPTLC) method for analysing Flupirtine maleate and Paracetamol in a combined dosage form.
 Method: Paracetamol and Flupirtine maleate were measured using a mobile phase of Ethyl acetate: Chloroform (7:5 v/v) at 286 nm. This technique was validated in accordance with the International Conference on Harmonization (ICH) guidelines.
 Results: The Rf value for paracetamol was 0.31 and 0.52 for Flupirtine maleate in this existing technique. Paracetamol's linearity was found to be in the range of 3250-6500 ng/band, while Flupirtine maleate's linearity was found to be in the range of 1000-2000 ng/band. The method's accuracy was determined by recovery experiments, which revealed a percent recovery of 98 to 102 percent. The % RSD was determined to be less than 2 in the Precision investigation, and the assay result for both compounds was within the limit.

Risk Assessment-Based Enhanced Analytical Quality-by-Design Approach to Eco-Friendly and Economical Multicomponent Spectrophotometric Methods for Simultaneous Estimation of Montelukast Sodium and Bilastine

Concomitant montelukast and bilastine are used as additive therapy for seasonal allergic rhinoconjuctivitis and mild to moderate asthma. According to a literature review, no UV-visible spectrophotometric method has been reported yet for simultaneous estimation of montelukast sodium and bilastine in their combined pharmaceutical dosage forms. Five different multicomponent spectrophotometric methods were therefore developed and validated for simultaneous estimation of montelukast sodium and bilastine using a risk assessment-based enhanced analytical quality-by-design approach. The identification and assessment of method risk parameters were carried out using the risk priority number ranking and filtering method according to the International Conference on Harmonization (ICH) Q9 guideline. The wavelength for detection and solvents such as 0.1 N NaOH and 0.1 N HCl were found to be critical method parameters for the development of the target methods. The developed methods were validated as per the ICH Q2(R1) guideline. The developed and validated methods were applied for assay of combined pharmaceutical dosage forms of montelukast sodium and bilastine and results were found to be in good agreement with their label claims. The developed methods did not include the usage of any organic solvent and are a good alternative to the costly chromatography method. Hence, the methods are eco-friendly and economical for the simultaneous estimation of bilastine and montelukast sodium. Five multicomponent spectrophotometric methods were developed for simultaneous estimation of montelukast sodium and bilastine using a risk-based analytical quality-by-design approach. An assay of combined tablet dosage forms of montelukast sodium and bilastine was then carried out using the developed methods.

Concurrent chromatographic determination of pseudoephedrine and loratadine from combination syrups and tablets

BackgroundChromatographic separation of polar and nonpolar compounds when presented in combined dosage forms has always been considered as great analytical challenge. Separation and retention of both polar and nonpolar compounds by the same stationary phase can be a useful approach for analyses of complex samples with such a difference in chemical properties. Loratadine (nonpolar) and pseudoephedrine (polar) are typical examples of this situation.ResultsThe Box–Behnken design was used to optimize the separation process, an efficient separation of loratadine and pseudoephedrine was achieved within 6 min; employing a mixture of 16.0 mM ammonium acetate buffer (pH 4.5) and acetonitrile (23:77, v/v) as isocratic mobile phase, pumped at 1.0 mL/min through a Zorbax cyanopropyl column (250 mm × 4.6 mm, 5 μm), the analytes were detected at 250 nm. Under the same conditions, separation of sodium benzoate preservative co-formulated with the two analytes in syrup formulation was also achieved. The calibration curve demonstrated excellent linearity in the range of 24.6–123.2 μg/mL and 594.8–2974.0 μg/mL for loratadine and pseudoephedrine, respectively with determination coefficient (r2) > 0.999.ConclusionThe method’s accuracy bias < 2.0%, repeatability and intermediate precision (%RSD < 2.0%) were verified. In addition, system suitability parameters were found within the acceptable limits. Satisfactory results were obtained upon the application of the validated method to the analysis of commercial tablet and syrup formulations.

Development and Validation of a Stability-Indicating HPLC-DAD Method for the Determination of Canagliflozin and Metformin Simultaneously in Combination Dosage Form

Development and Validation of a Stability-Indicating HPLC-DAD Method for the Determination of Canagliflozin and Metformin Simultaneously in Combination Dosage Form

A rapid RP-HPLC method for the simultaneous estimation of Ivacaftor and Tezacaftor and in silico study of their metabolitic products

BackgroundThis study was designed to develop a reliable method for estimation of Ivacaftor and Tezacaftor in pure and its pharmaceutical dosage form by RP-HPLC in human plasma. Molecular docking studies were carried out and the results were visualized using PyMol and Discovery studio visualizer (Discovery studio visualizer ver. 2.5). The pharmacokinetic properties such as Swiss ADME and pKCSM of the Ivacaftor and its metabolites Ivacaftor M1, M6 and Tezacaftor and metabolites Tezacaftor M1, M2 were predicted. In admetSAR, web-based query tools incorporating a molecular built-in interface enable the database to be queried by SMILES.ResultsA simple, linear, precise, and accurate RP-HPLC method was developed and validated for the determination of Ivacaftor (IVA) and Tezacaftor (TEZ) in human plasma. Chromatographic separation was achieved isocratically on Inspire C18, (4.6 × 250 mm, 5 μm) column at 30 °C. Mobile phase consisting of methanol and 0.05% formic acid in ratio of 95:5 with flow rate of 1 mL/min with injection volume 20 μl detector used is PDA at 235 nm. The developed method was validated according to ICH guidelines and found to be linearity range was found to be for TEZ (10–50 μg/mL) and IVA (15–75 μg/mL). IVA and TEZ drugs and its metabolites were retrieved from the PubChem database and the 2D chemical structures were generated from SMILES notation by using the Chemsketch Software. The structure was viewed using Swiss-PDB Viewer to form a better understanding of the molecule for toxicity and biological activity prediction.ConclusionThe results obtained by the proposed method from validation parameters and from assay confirmed that the determination of Tezacaftor (TEZ) and Ivacaftor (IVA) in their combined dosage form in human plasma was sensitive and selective method. In silico study has revealed that IVA and its metabolites IVA M1, IVA M6 are according to Lipinski rule. The oral bioactivity of IVA was found to be more when compared to its metabolites (Molinspiration) and TEZ and its metabolites TEZ M1, TEZ M2 even though they have the molecular weight > 500, but all other parameters from Molinspiration revealed better oral bioactivity of TEZ M2. Validation of the developed isocratic RP-HPLC procedure revealed that, regardless of how the sample was purified, the method was characterized by good linearity, sensitivity, reproducibility, specificity, and low values of LOD (0.090 μg/mL) and LOQ (0.275 μg/mL). From the in silico docking results, it is quite evident that metabolites of TEZ and IVA have the great potential against cystic fibrosis.

Validated RP-HPLC method for the estimation of nebivolol hydrochloride and valsartan in combined tablet dosage form

The intention of this work is to develop a rapid, precise, accurate and sensitive reverse phase liquid chromatographic technique for the simultaneous estimation of Nebivolol and Valsartan in tablet dosage form. The chromatographic method was standardized using Inertsil ODS column (250×4.6mm, 5μm particle size) with UV detection at 278nm and flow rate of 1ml/min. The mobile phase comprises of ACN: Buffer (pH adjusted to 3.5 with dilute Ortho Phosphoric acid) in the fraction of 60:40 v/v. The linearity of proposed method was investigated in the range of 12.5-62.5μg/ml (R²=0.999) for Nebivolol and 200-1000μg/ml(R²=0.999) for Valsartan duly. The limit of detection (LOD) was found to be 0.05μg/ml and 0.81μg/ml for Nebivolol and Valsartan duly. The limit of quantification (LOQ) was found to be 0.15μg/ml and 2.44μg/ml for Nebivolol and Valsartan respectively. The retention time of Nebivolol and Valsartan were ground in to be 4.400min and 2.568min respectively. The method was authentically suggested and % RSD was ground in to be less than 2 indicating high degree of accuracy and precision. Hence proposed method can be successfully graded for the simultaneous estimation of Nebivolol and Valsartan in marketed formulation.

Smart UV-Spectrophotometric methods for the simultaneous determination of amprolium-HCl, ethopabate and sulfaquinoxaline-Na in combined dosage forms

Two UV-spectrophotometric methods were adopted for simultaneous determination of amprolium HCl, ethopabate and sulfaquinoxaline-Na. The two methods are a double divisor ratio derivative method and ratio dual wavelength method. The three cited drugs were determined by the suggested methods in the range of 6.0-50.0 µg mL-1, 2.0-27.0 μg mL-1 and 3.0-25.0 µg mL-1, respectively. The proposed methods were proved to be selective where the mean percentage recoveries of amprolium HCL, ethopabate and sulfaquinoxaline-Na provided by the double divisor ratio derivative method were 99.29 ± 0.84, 100.36 ± 1.21 and 100.61-101.57 ± 0.15-1.75; respectively. The ratio dual wavelength method mean recoveries were in the range of 98.93-100.45%±0.44-1.42, 99.47-100.67%±0.83-1.65 and 99.97-101.71%±0.10-1.15 for the studied drugs; respectively. Both methods were validated following ICH guidelines. Successful application of the methods for analyzing the three drugs in their veterinary dosage forms; Ampoethoquinone powder was conducted. The obtained results were statistically analyzed and found to be in accordance with those given by the reported methods.

Stability Indicating Simultaneous Estimation of Cetirizine Hydrochloride and Phenylephrine Hydrochloride in Combined tablet formulation by using HPTLC- Densitometric method

The new simple, precise, rapid, selective, high performance thin layer chromatography method has been developed for simultaneous estimation of cetirizine hydrochloride and phenylephrine hydrochloride in its combined solid dosage form. The HPTLC method was performed on precoated silica gel G60 F254 plates with, Toluene: Methanol: Ammonia (8: 2: 1, v/v/v) as optimum mobile phase. The plates were developed in 6.00× 0.30mm at room temperature. The developed plates were scanned and quantified at their absorption at 224 nm for CET and PHE respectively. The drugs were satisfactorily resolved with Rf = 0.36± 0.001 for CET and 0.65±0.004 for PHE. Calibration plot was linear between 100-600 ng/ spot for CET and 200-1200 ng/ spot for PHE. This HPTLC method is sensitive, economical, less time consuming than other chromatographic procedures. It can become important tool for analysis of combined solid dosage from. In addition to this results acid exposure, base exposure, oxidative exposure, neutral exposure, photolysis and dry heat exposure is carried out.

Mathematical filtration of quaternary mixture to the zero order spectra of its individual components

Simple accurate and precise validated UV spectrophotometric methods have been described here for the simultaneous determination of Tretinoin (TN) Eusolex (EX) Hydroquinone (HQ) & Hydrocortisone acetate (HC) in their dosage form. Simultaneous determination of these four drugs was a major challenge till now. Each spectrum was filtered alone to its zero-order absorption spectrum (D0) form getting spectra typical to each pure component separately. Four methods were applied depending upon constants obtained from extended regions of partially overlapped spectra in the zero or first derivative forms. The methods applied are constant multiplication coupled with spectrum subtraction method (CM-SS) derivative transformation coupled with spectrum subtraction method (DT-SS) constant value method (CV) and concentration value (conc.value) method. The partially overlapped spectra of TN and EX in the mixture were obtained by CM-SS in their zero-order form allowing direct measurement at their λmax while the resolved binary mixture of HQ and HC obtained by SS; was determined by derivatization and transformed to their zero order by DT-SS. Also Ex and HQ concentrations were determined by the graphical representation of data only without regression equation by concentration value method and the results were compared to the conventional constant value method using a regression equation. The methods applied to the quaternary mixture under study were successfully applied for the simultaneous determination of the four drugs in synthetic mixtures and in their combined dosage form Tritospot® cream. Comparing the acquired results statistically together and to official methods demonstrated no significant difference.

RP-HPLC Accelerated Degradation Method Development and Validation for Determination of Amlodipine and Atorvastatin in Combination Dosage Form of Tablet

Abstract: Aim: The Cost effective, Accurate, Precise Accelerated degradation method has been developed for determination of Atorvastatin and Amlodipine in combination dosage form of tablet and validated as directed by ICH guidelines. Objectives: To develop and validate analytical method which can be easily adoptable in frequent analysis of Amlodipine and Atorvastatin combinations in the laboratories. Materials and Methods: The 0.02 M potassium dihydrogen phosphate: acetonitrile: methanol (30:10:60 v/v/v) was used as mobile phase and pH 4 adjusted using ortho phosphoric acid at flow rate 1.0 ml/min. The column used for method development was Octadecylsilane-C18 (5 μm, 25 cm × 4.6mm, i. d.). The peaks obtained in the chromatogram were well resoluted. The scanning wavelength used was 244 nm with PDA detector. Results: The linearity for both the drugs was found between 05 - 30 μg/ml for both drugs with regression coefficient equation 0.995 and 0.999 at retention time 8.32 min and 11.09 min for Amlodipine and Atorvastatin respectively. The results obtained were statistically validated as directed by ICH guidelines and was found satisfactory. Conclusion: The developed and validated method was found to be very specific, accurate and precise. It can be utilized for routine analysis of combined dosage form of Amlodipine and Atorvastatin in the laboratory. Key words: Amlodipine, Atorvastatin, RP-HPLC, ICH Guidelines, PDA Detector, Validation.

Development of rapid and simple spectrophotometric method for the simultaneous determination of anti-parkinson drugs in combined dosage form using continuous wavelet transform and radial basis function neural network

In this study, simultaneous measurements of levodopa (LD), carbidopa (CD), and entacapone (ENT) as anti-parkinson drugs were investigated in synthetic mixtures and Staparkin tablet by continuous wavelet transform (CWT) and radial basis function neural network (RBF-NN) along with spectrophotometric method. In the CWT method, based on the best zero crossing point and R squared (R2) related to the calibration solutions, the Symlet with second order (Sym2), the Daubechies with second order (Db2), and Gaussian as wavelet families were selected for LD, CD, and ENT, respectively. Limit of detection (LOD) and limit of quantification (LOQ) of standard samples for LD, CD, and ENT were 0.0076, 0.159, 0.1519 and 0.0055, 0.0148, 0.3854 μg mL−1, respectively. Also, the average recovery of synthetic mixtures, containing LD, CD, and ENT was obtained 100.23%, 100.01%, and 99.88%, respectively. In the RBF-NN model, root mean square error (RMSE) of 1.14 × 10−27, 2.94 × 10−14, and 8.675 × 10−15 were found for LD, CD, and ENT, respectively. The comparison of proposefd methods with each other was performed on a commercial tablet sample through analysis of variance (ANOVA) test at 95% confidence level. In addition, the standard addition technique was applied to evaluate the performance of these methods in complex matrix. Due to the fast, simple, inexpensive, accurate, as well as without need separation steps, the proposed method can compete with high-performance liquid chromatography (HPLC).

Simultaneous determination of ezetimibe, atorvastatin and simvastatin using quadrupole LC-MS: Application to combined tablets and plasma after SPE

AbstractA simple and sensitive liquid chromatography-mass spectrometric (LC-MS) method has been developed and validated for the simultaneous determination of ezetimibe (EZE), atorvastatin calcium (ATO), and simvastatin (SMV) in combined dosage forms and human plasma. Successful separation of the studied drugs was achieved on a Zorbax Eclipse Plus C18 column (3.0 × 150 mm, 5 µm) using a mobile phase consisting of acetonitrile and 0.1% formic acid in water (65:35, v/v) at a flow rate of 0.5 mL min−1. Total run time was 9.3 min and diclofenac sodium was used as internal standard (IS). Positive selected ion monitoring (SIM) mode was applied where, the monitored ions were those at m/z values of 392.1, 559.3, 296.0, and 441.4 corresponding to EZE, ATO, IS, and SMV, respectively. The method was fully validated according to the ICH guidelines. The intraday and interday precision showed relative SD values not more than 1.77 and 1.99%; respectively. The limits of detection (LOD) were 0.25, 0.25, and 0.75 ng mL−1 while the limits of quantification (LOQ) were 1.25, 0.75, and 2.5 ng mL−1 for EZE, ATO, and SMV, respectively. The developed method was applied on two types of combined tablets concerning drug assay with mean percent recoveries within acceptable range. The method has been extended to the determination of the studied drugs in human plasma where, a solid phase extraction method was optimized for their extraction with percent recovery not less than 97%.

Enabling modular dosage form concepts for individualized multidrug therapy: Expanding the design window for poorly water-soluble drugs

Multidrug dosage forms (aka combination dosage forms, polypills, etc.) create value for patients through reduced pill burdens and simplified administration to improve adherence to therapy. Enhanced flexibility of multidrug dosage forms would provide further opportunities to better match emerging needs for individualized therapy. Through modular dosage form concepts, one approach to satisfy these needs is to adapt multidrug dosage forms to a wider variety of drugs, each with a variety of doses and release profiles. This study investigates and technically explores design requirements for extending the capability of modular multidrug dosage form concepts towards individualization. This builds on our recent demonstration of independent tailoring of dose and drug release, which is here extended towards poorly water-soluble drugs. The challenging design requirement of carrying higher drug loads in smaller volumes to accommodate multiple drugs at their clinical dose is here met regarding dose and release performance. With a modular concept, we demonstrate high precision (<5% RSD) in dose and release performance of individual modules containing felodipine or naproxen in Kollidon VA64 at both a wide drug loading range (5% w/w and 50% w/w drug) and a small module size (3.6 mg). In a forward-looking design-based discussion, further requirements are addressed, emphasizing that reproducible individual module performance is predictive of dosage form performance, provided the modules are designed to act independently. Therefore, efforts to incorporate progressively higher drug loads within progressively smaller module volumes will be crucial to extend the design window further towards full flexibility of future dosage forms for individualized multidrug therapy.

Three Different Approaches Based on Derivative Ratio Spectra for Spectrophotometric Resolution of a Quaternary Mixture in Semisolid Dosage Form.

Recent incorporated spectrophotometer software supporting mathematical methods was considered as an optimum key for the resolution of multicomponent mixtures. Several spectrophotometric techniques are introduced for the determination of mixtures of tretinoin (TN), hydroquinone (HQ), and fluocinolone acetonide (FA), in the presence of the preservative methyl paraben (MP), without any separation procedure, taking into consideration the presence of two minor components and the severe overlap of their spectra. Constant multiplication coupled spectrum subtraction resolved the quaternary mixture into the zero-order absorption spectrum of TN alone and a severely overlapped, ternary mixture of HQ, FA, and MP. Three approaches based on the derivative ratio spectra were applied to resolve this ternary, severely overlapped mixture: derivative ratio-zero-crossing point method, factorized derivative ratio method, and double divisor derivative ratio method. The work was conducted over a concentration range of 1-10, 4-38, and 4-35 µg/mL, for TN, HQ, and FA, respectively. The results obtained were compared statistically to each other and to the official methods, showing no significant difference. The proposed methods were successfully applied for the simultaneous determination of the three drugs in the presence of MP in synthetic mixtures and in their combined dosage form (Trimelasma® cream) with very good accuracy and precision. This was a comparative study between conventional and new methods for resolving ternary, severely overlapped mixtures. Mathematical manipulation steps and enrichment techniques aided accurate quantification of the minor components in mixtures.

Application of Simultaneous Equation method for estimation of Sacubitril and Valsartan in Combined Dosage Form

Application of Simultaneous Equation method for estimation of Sacubitril and Valsartan in Combined Dosage Form

Development and Validation of Q-Absorbance Ratio by UV-Spectrophotometric Method for Simultaneous Estimation of Metformin and Empagliflozin in Bulk and Combined Dosage Form

Advantages of simultaneous stability studies are the identification of new degradation products, to understand mutual induction and/or inhibition of rates of degradation and to analyze the degradation products of both drugs. Various ultraviolet spectroscopic and high performance liquid chromatographic assay methods were reported for the estimation of metformin, sitagliptin, pioglitazone, glimepiride and simvastatin individually and in combination with other drugs. All the above reported methods were based on the estimation of metformin, sitagliptin, pioglitazone, glimepiride and simvastatin alone or in combination with other drugs. The degradation products were generated and successfully separated by the developed and validated high performance liquid chromatographic methods for the estimation of the selected anti-diabetic drug combinations. The aim of the study was to develop and validate of Q-Absorbance Ratio UV-Spectrophotometric Method for Simultaneous Estimation of Metformin and Empagliflozin in Bulk and Combined Dosage Form.&#x0D; Keywords: Metformin, Method Development, Validation, Empagliflozin, UV-Spectrophotometer.

HPLC Method Development, Validation and Stability Study of Metformin, Voglibose and Teneligliptin in Bulk and Combined Dosage Form

HPLC Method Development, Validation and Stability Study of Metformin, Voglibose and Teneligliptin in Bulk and Combined Dosage Form

Microbiological justification of the application of cyprofloxacin and tinidazole combination for antimicrobial chemistry in dentistry

Relevance. According to modern concepts, virulent representatives of periodontal pathogenic bacteria are actively involved in the development of both periodontal pathology and various forms of odontogenic infection. The species diversity of these pathogens determines the need for a combined approach when choosing antimicrobial drugs.The aim of the work is to provide a microbiological substantiation of the use of a combined dosage form of ciprofloxacin and tinidazole for the treatment of periodontal and odontogenic infections based on the determination of the spectrum of action and the characteristics of the activity of the components.Materials and methods. Determination of the sensitivity of various strains of periodontal and odontogenic infection pathogens (P. intermedia, S. constellatus; S. sanguis, K. pneumoniae, S. aureus – MRSA) was carried out by the method of automated cultivation of strains with different concentrations of the tested drugs – ciprofloxacin and tinidazole.Results. Differences in the activity of the components of the combined preparation ciprofloxacin and tinidazole were found in terms of the sensitivity of strains of aerobic and anaerobic pathogens to them. Aerobic strains, including MRSA, were inhibited by ciprofloxacin in a low concentration range (6.25 μg / ml), but for some anaerobic strains the activity of ciprofloxacin was borderline (12.5 μg / ml). This confirmed the need to include tinidazole in the composition of the complex preparation.Conclusion. The combination of ciprofloxacin and tinidazole provides coverage of the full spectrum of periodontal and odontogenic infections and can be used as the agent of choice in the antimicrobial chemotherapy algorithm for head and neck infections.